IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Biotechnology

Healthcare
$26.49 -1.45%

-$0.45 today

Market cap
$2.56B
Beta
-0.05
P/E (TTM)
-19.5
EPS (TTM)
-$1.58
52W Low $20.50High $39.28

Volume 1.45M

Average 1.44M

IDYA Deferred Revenue (Non-current)

Payments received for goods or services the company will deliver after more than one year.

IDEAYA Biosciences, Inc.NASDAQ: IDYA

Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue (non-current) remains negative

Q1 FY2026 deferred revenue (non-current) was $0, compared with $0 a year earlier.

Context

  • Deferred revenue (non-current) amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Deferred revenue (non-current) increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Deferred Revenue (Non-current) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue (Non-current) history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Revenue (Non-current) vs competitors

How IDYA compares with its peers on the latest reported figures

  • IDYA's Mar 2026 deferred revenue (non-current) of $0 is the 3rd highest of the 9 companies compared; the peer median is $0.
  • Deferred revenue (non-current) amounts to 0.0% of total assets for IDYA, versus a peer median of 0.0%.
IDYA Competitors Peer median
Deferred Revenue (Non-current) for IDYA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
FHTXFoghorn Therapeutics Inc.Mar 2026$193.59M -13.0%-12.2%87.1%
NRIXNurix Therapeutics, Inc.Aug 2026$10.78M -29.0%-34.7%0.9%
IDYAIDEAYA Biosciences, Inc.Mar 2026$0 ——0.0%
RVMDRevolution Medicines, Inc.Jun 2026$0 ——0.0%
ERASErasca, Inc.Sep 2026$0 ——0.0%
COGTCogent Biosciences, Inc.Jun 2026$0 ——0.0%
TNGXTango Therapeutics, Inc.Sep 2026$0 ——0.0%
VSTMVerastem, Inc.Mar 2026$0 ——0.0%
PRLDPrelude Therapeutics IncorporatedMar 2026$0 ——0.0%
Peer median (excluding IDYA) $0-21.0%-23.4%0.0%

Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents92.05M68.63M157.02M84.38M112.83M
Short-term Investments154.72M296.2M368.1M591.94M526.56M
Net Receivables1.1M211K18K3K5.97M
Inventory00000
Other Current Assets05.41M7.5M13.39M21.37M
Total Current Assets251M370.45M532.63M689.71M666.73M
Property, Plant & Equipment (Net)8.66M8.99M8.41M27.74M31.29M
Goodwill00000
Intangible Assets00000
Long-term Investments121.29M8.32M107.49M405.83M410.3M
Tax Assets00000
Other Non-current Assets397K205K782K805K1.02M
Total Non-current Assets130.35M17.52M116.68M434.38M442.6M
Total Assets381.35M387.97M649.32M1.12B1.11B
Account Payables2.1M4.28M6.6M15.42M17.58M
Short-term Debt0000339K
Tax Payables00000
Deferred Revenue29.04M8.57M000
Other Current Liabilities0011.78M30.35M29.69M
Total Current Liabilities45.16M31.72M27.1M46.07M58.82M
Long-term Debt000027.58M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)31.19M5.19M000
Other Non-current Liabilities00000
Total Non-current Liabilities34.67M6.8M1.13M18.87M27.58M
Total Liabilities79.83M38.51M28.23M64.94M86.39M
Common Stock4K5K7K9K9K
Retained Earnings(176.75M)(235.4M)(348.36M)(622.84M)(736.54M)
Accumulated OCI(712K)(2.87M)562K812K2.27M
Other Stockholders Equity00000
Minority Interest00000
Total Equity301.51M349.46M621.09M1.06B1.02B
Total Debt5.18M3.48M2.87M19.17M27.91M
Net Debt(86.87M)(65.15M)(154.15M)(65.21M)(84.91M)

IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Intrinsic Alpha fair value

Locked

Current Price

$26.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.